Menu Search
Equities

Cytosorbents Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HQE1:FRA

Cytosorbents Corp

Actions
  • Price (EUR)0.5030
  • Today's Change-0.03 / -5.63%
  • Shares traded3.11k
  • 1 Year change-49.80%
  • Beta1.4094
Data delayed at least 15 minutes, as of Feb 12 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

  • Revenue in USD (TTM)34.35m
  • Net income in USD-10.59m
  • Incorporated2014
  • Employees149.00
  • Location
    Cytosorbents Corp305 COLLEGE ROAD EASTPRINCETON 08540United StatesUSA
  • Phone+1 (973) 329-8885
  • Websitehttps://cytosorbents.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.